Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells

Toxicology and Applied Pharmacology

Volumn 255, Issue 3, 2011, Pages 271-286

  El Awady, Raafat A ^a,b   Saleh, Ekram M ^a   Ezz, Marwa ^c   Elsayed, Abeer M ^d  

^a CAIRO UNIVERSITY   (Egypt)

^b UNIVERSITY OF SHARJAH   (United Arab Emirates)

^c CAIRO UNIVERSITY   (Egypt)

^d NATIONAL CANCER INSTITUTE   (Egypt)

Author keywords

Apoptosis; Celecoxib; Cell cycle; MCF7; Pharmacological interaction

Indexed keywords

CELECOXIB; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL STRAIN HCT116; CELL STRAIN HEPG2; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA DAMAGE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HELA CELL; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DRUG INTERACTIONS; FEMALE; HCT116 CELLS; HELA CELLS; HEP G2 CELLS; HUMANS; PYRAZOLES; SULFONAMIDES;

EID: 81155126448     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.06.019     Document Type: Article

References (41)

1. Baron J.A., Cole B.F., Sandler R.S., Haile R.W., Ahnen D., Bresalier R., McKeown-Eyssen G., Summers R.W., Rothstein R., Burke C.A., Snover D.C., Church T.R., Allen J.I., Beach M., Beck G.J., Bond J.H., Byers T., Greenberg E.R., Mandel J.S., Marcon N., Mott L.A., Pearson L., Saibil F., Van Stolk R.U. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 2003, 348:891-899.
2. Berenbaum M. What is synergy?. Pharmacol. Rev. 1989, 41:93-141.
3. Bhatt R.S., Merchan J., Parker R., Wu H.K., Zhang L., Seery V., Heymach J.V., Atkins M.B., McDermott D., Sukhatme V.P. A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 2010, 116(7):1751-1756.
4. Bijman M.N., Hermelink C.A., Van Berkel M.P., Laan A.C., Janmaat M.L., Peters G.J., Boven E. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem. Pharmacol. 2008, 75:427-437.
5. Bol D.K., Rowley R.B., Ho C.P., Pilz B., Dell J., Swerdel M., Kiguchi K., Muga S., Klein R., Fischer S.M. Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumour development. Cancer Res. 2002, 62:2516-2521.
6. Chen W.S., Wei S.J., Liu J.M., Hsiao M., Kou-Lin J., Yang W.K. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2 selective inhibitor, etodolac. Int. J. Cancer 2001, 91:894-899.
7. Chen W., Liu J., Liu J., Lin J. Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells. Anticancer Drugs 2004, 15:287-294.
8. Chen C., Shen H.L., Yang J., Chen Q.Y., Xu W.L. Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. J. Cancer Res. Clin. Oncol. 2011, 137(1):9-17.
9. Chuang H., Kardosh A., Gaffney K.J., Petasis N.A., Schönthal A.H. COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol. Cancer 2008, 7:38.
10. Dandekar D.S., Lopez M., Carey R.I., Lokeshwar B.L. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int. J. Cancer 2005, 115:484-492.
11. Dhawan D., Craig B.A., Cheng L., Snyder P.W., Mohammed S.I., Stewart J.C., Zheng R., Loman R.A., Foster R.S., Knapp D.W. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol. Cancer Ther. 2010, 9(5):1371-1377.
12. El-Awady R.A., Dikomey E., Dahm-Daphi J. Radiosensitivity of human tumour cells is associated with the induction but not with the repair of DNA double-strand breaks. Br. J. Cancer 2003, 89:593-601.
13. El-Rayes B.F., Zalupski M.M., Shields A.F., Ferris A.M., Vaishampayan U., Heilborn L.K., Venkatramanamoorthy R., Adsay V., Philip P.A. A phase II study of celecoxib, Gemcitabine, and cisplatin in advanced pancreatic cancer. Invest. New Drugs 2005, 23:583-590.
14. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 2000, 30:3-21.
15. Han C., Leng J., Demetris A.J., Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidencefor cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res. 2004, 64:1369-1376.
16. Hashitani S., Urade M., Nishimura N., Maeda T., Takaoka K., Noguchi K., Sakurai K. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int. J. Oncol. 2003, 23:665-672.
17. Hung W.C., Chang H.C., Pan M.R., Lee T.H., Chuang L.Y. Induction of p27KIP1 as a mechanism underlying NS398- induced growth inhibition in human lung cancer cells. Mol. Pharmacol. 2000, 58:1398-1403.
18. Jolly K., Cheng K.K., Langman M.J. NSAIDs and gastrointestinal cancer prevention. Drugs 2002, 62:945-956.
19. Kakiuchi Y., Tsuji S., Tsujii M., Murata H., Kawai N., Yasumaru M., Kimura A., Komori M., Irie T., Miyoshi E., Sasaki Y., Hayashi N., Kawano S., Hori M. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res. 2002, 62:1567-1572.
20. Kase S., Osaki M., Honjo S., Takeda A., Adachi K., Araki K., Ito H. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2-M phase in human esophageal squamous cell carcinoma cells. J. Exp. Clin. Cancer Res. 2004, 23:301-307.
21. Kim S., Kim S., Song Y., Song Y. Celecoxib potentiates the anticancer effects of cisplatin on vulvar cancer cells independently of cyclooxygenase. Ann. N. Y. Acad. Sci. 2009, 1171:635-641.
22. Leahy K.M., Koki A.T., Masferrer J.L. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem. 2000, 7:1163-1170.
23. Li H.L., Zhang H.W., Chen D.D., Zhong L., Ren X.D., St-Tu R. JTE-522, a selective COX-2 inhibitor, inhibits cell proliferation and induces apoptosis in RL95-2 cells. Acta Pharmacol. Sin. 2002, 23:631-637.
24. Lin M.T., Lee R.C., Yang P.C., Ho F.M., Kuo M.L. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. J. Biol. Chem. 2001, 276:48997-49002.
25. Maier T.J., Schilling K., Schmidt R., Geisslinger G., Grosch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 2004, 67(8):1469-1478.
26. Nakopoulou L., Mylona E., Papadaki I., Kapranou A., Giannopoulou I., Markaki S.K., Eramopoulos A. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathology 2005, 72:241-249.
27. Narayanan B.A., Condon M.S., Bosland M.C., Narayanan N.K., Reddy B.S. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin. Cancer Res. 2003, 9:3503-3513.
28. Nzeako U.C., Guicciardi M.E., Yoon J.H., Bronk S.F., Gores G.J. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 2002, 35:552-559.
29. Pierga J., Delaloge S., Espie M., Brain E., Sigal-Zafrani B., Mathieu M., Bertheau P., Guinebretière J.M., Spielmann M., Savignoni A., Marty M. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res. Treat. 2010, 122:429-437.
30. Schönthal A.H. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br. J. Cancer 2007, 97(11):1465-1468.
31. Schönthal A.H., Chen T.C., Hofman F.M., Louie S.G., Petasis N.A. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin. Investig. Drugs 2008, 17(2):197-208.
32. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer drug screening. J. Natl. Cancer Inst. 1990, 82:1107-1112.
33. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., Koki A.T. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000, 89:2637-2645.
34. Stempak D., Gammon J., Klein J., Koren G., Baruchel S. Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin. Pharmacol. Ther. 2002, 72:490-497.
35. Tsujii M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U S A 1997, 94:3336-3340.
36. Van Wijngaarden J., Van Beek E., Van Rossum G., Van der Bent C., Hoekman K., Van der Pluijm G., Van der Pol M.A., Broxterman H.J., Van Hinsbergh V.W., Löwik C.W. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-κB-mediated increase of intracellular doxorubicin accumulation. Eur. J. Cancer 2007, 43:433-442.
37. Wang D., Dubois R.N. Prostaglandins and cancer. Gut 2006, 55:115-122.
38. Williams C.S., Watson A.J., Sheng H., Helou R., Shao J., DuBios R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 2000, 60:6045-6051.
39. Xu Z., Choudhary S., Voznesensky O., Mehrotra M., Woodard M., Hansen M., Herschman H., Pilbeam C. Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. Cancer Res. 2006, 66:6657-6664.
40. Yamashita H., Osaki M., Honjo S., Yoshida H., Teshima R., Ito H. A selective cyclooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line. Anticancer. Res. 2003, 23:4671-4676.
41. Zhu J., Song X., Lin H.P., Young D.C., Yan S., Marquez V.E., Chen C.S. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J. Natl. Cancer Inst. 2002, 94(23):1745-1757.